Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics

Bremelanotide (Vyleesi®), a cyclic heptapeptide, was recently approved for the subcutaneous treatment of premenopausal hypoactive sexual desire disorder. To foster the development of alternative routes of administration, we aimed at determining the oral plasma pharmacokinetics of bremelanotide in be...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sauter, Max (VerfasserIn) , Uhl, Philipp (VerfasserIn) , Burhenne, Jürgen (VerfasserIn) , Haefeli, Walter E. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 27 March 2020
In: Journal of pharmaceutical and biomedical analysis
Year: 2020, Jahrgang: 186
ISSN:1873-264X
DOI:10.1016/j.jpba.2020.113276
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jpba.2020.113276
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0731708520302375
Volltext
Verfasserangaben:Max Sauter, Philipp Uhl, Jürgen Burhenne, Walter E. Haefeli

MARC

LEADER 00000caa a2200000 c 4500
001 1724812653
003 DE-627
005 20230426103241.0
007 cr uuu---uuuuu
008 200715s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.jpba.2020.113276  |2 doi 
035 |a (DE-627)1724812653 
035 |a (DE-599)KXP1724812653 
035 |a (OCoLC)1341345356 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Sauter, Max  |e VerfasserIn  |0 (DE-588)1103516507  |0 (DE-627)86126813X  |0 (DE-576)470642033  |4 aut 
245 1 0 |a Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics  |c Max Sauter, Philipp Uhl, Jürgen Burhenne, Walter E. Haefeli 
264 1 |c 27 March 2020 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 15.07.2020 
520 |a Bremelanotide (Vyleesi®), a cyclic heptapeptide, was recently approved for the subcutaneous treatment of premenopausal hypoactive sexual desire disorder. To foster the development of alternative routes of administration, we aimed at determining the oral plasma pharmacokinetics of bremelanotide in beagle dogs. Therefore, we established a UHPLC-MS/MS assay with an LLOQ of 10 pg/mL (9.8 pM) using 100 μL of plasma and validated it according to the guidelines of the US Food and Drug Administration and the European Medicines Agency. Bremelanotide was isolated from plasma by protein precipitation and quantification was performed with positive heated ESI MS/MS in the SRM mode. The calibrated concentration range of 10−10,000 pg/mL was linear showing correlation coefficients > 0.99. In the calibrated range, interday and intraday accuracy ranged from 88.9-100.0 % with corresponding precision < 8 %. Accuracy at the LLOQ ranged from 93.6-100.8 % with corresponding precision < 11 %. Because of the validity of a dilution QC that showed accurate quantification of 10-fold diluted plasma samples (accuracy 99.4 %, precision < 6 %), the assay is suitable for bremelanotide quantification in its effective concentration range up to 100,000 pg/mL. The ultra-sensitive assay was applied to the quantification of bremelanotide plasma concentrations after oral administration to beagle dogs, which indicated minimal oral absorption. 
650 4 |a Beagle dog 
650 4 |a Bremelanotide 
650 4 |a Oral administration 
650 4 |a Pharmacokinetics 
650 4 |a Plasma 
650 4 |a UHPLC-MS/MS 
700 1 |a Uhl, Philipp  |e VerfasserIn  |0 (DE-588)1112349391  |0 (DE-627)866420797  |0 (DE-576)476575230  |4 aut 
700 1 |a Burhenne, Jürgen  |d 1963-  |e VerfasserIn  |0 (DE-588)1034228889  |0 (DE-627)745126987  |0 (DE-576)381858197  |4 aut 
700 1 |a Haefeli, Walter E.  |d 1958-  |e VerfasserIn  |0 (DE-588)124572359  |0 (DE-627)656806141  |0 (DE-576)340514221  |4 aut 
773 0 8 |i Enthalten in  |t Journal of pharmaceutical and biomedical analysis  |d New York, NY [u.a.] : Science Direct, 1983  |g 186(2020) Artikel-Nummer 113276, 6 Seiten  |h Online-Ressource  |w (DE-627)30271801X  |w (DE-600)1491820-1  |w (DE-576)259483931  |x 1873-264X  |7 nnas  |a Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics 
773 1 8 |g volume:186  |g year:2020  |g extent:6  |a Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics 
856 4 0 |u https://doi.org/10.1016/j.jpba.2020.113276  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0731708520302375  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200715 
993 |a Article 
994 |a 2020 
998 |g 124572359  |a Haefeli, Walter E.  |m 124572359:Haefeli, Walter E.  |d 910000  |d 910100  |e 910000PH124572359  |e 910100PH124572359  |k 0/910000/  |k 1/910000/910100/  |p 4  |y j 
998 |g 1034228889  |a Burhenne, Jürgen  |m 1034228889:Burhenne, Jürgen  |d 910000  |d 910100  |e 910000PB1034228889  |e 910100PB1034228889  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 1112349391  |a Uhl, Philipp  |m 1112349391:Uhl, Philipp  |d 910000  |d 911400  |e 910000PU1112349391  |e 911400PU1112349391  |k 0/910000/  |k 1/910000/911400/  |p 2 
998 |g 1103516507  |a Sauter, Max  |m 1103516507:Sauter, Max  |d 910000  |d 910100  |e 910000PS1103516507  |e 910100PS1103516507  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1724812653  |e 3724432968 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"origin":[{"publisherPlace":"New York, NY [u.a.]","publisher":"Science Direct","dateIssuedKey":"1983","dateIssuedDisp":"1983-"}],"id":{"issn":["1873-264X"],"zdb":["1491820-1"],"eki":["30271801X"]},"part":{"year":"2020","volume":"186","text":"186(2020) Artikel-Nummer 113276, 6 Seiten","extent":"6"},"recId":"30271801X","disp":"Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokineticsJournal of pharmaceutical and biomedical analysis","title":[{"subtitle":"the official analytical journal of the American Association of Pharmaceutical Scientists","title":"Journal of pharmaceutical and biomedical analysis","title_sort":"Journal of pharmaceutical and biomedical analysis"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.1983 -"],"language":["eng"]}],"note":["Gesehen am 15.07.2020"],"origin":[{"dateIssuedDisp":"27 March 2020","dateIssuedKey":"2020"}],"id":{"doi":["10.1016/j.jpba.2020.113276"],"eki":["1724812653"]},"recId":"1724812653","name":{"displayForm":["Max Sauter, Philipp Uhl, Jürgen Burhenne, Walter E. Haefeli"]},"title":[{"title_sort":"Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics","title":"Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics"}],"person":[{"family":"Sauter","given":"Max","role":"aut","display":"Sauter, Max"},{"given":"Philipp","role":"aut","family":"Uhl","display":"Uhl, Philipp"},{"display":"Burhenne, Jürgen","family":"Burhenne","given":"Jürgen","role":"aut"},{"display":"Haefeli, Walter E.","family":"Haefeli","role":"aut","given":"Walter E."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"physDesc":[{"extent":"6 S."}]} 
SRT |a SAUTERMAXUULTRASENSI2720